Detalhe da pesquisa
1.
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Blood
; 138(22): 2231-2243, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407546
2.
Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.
Haematologica
; 104(1): 70-81, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171023
3.
Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.
Am J Pathol
; 187(8): 1879-1892, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28728747
4.
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Blood
; 127(10): 1317-24, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26608331
5.
Megakaryocytes tame erythropoiesis with TGFß1.
Blood
; 136(9): 1016-1017, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32853376
6.
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.
Blood
; 124(7): 1136-45, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24951423
7.
JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.
J Cell Mol Med
; 19(11): 2564-74, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26176817
8.
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Blood
; 122(8): 1464-77, 2013 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23863895
9.
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Blood
; 119(20): 4625-35, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22378845
10.
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.
Blood
; 119(5): 1190-9, 2012 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22065597
11.
Exacerbation of thrombo-inflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis.
Blood Adv
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386979
12.
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
J Cell Mol Med
; 17(11): 1385-96, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24237791
13.
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
J Cell Mol Med
; 17(11): 1397-409, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24251790
14.
Endothelial JAK2V617F does not enhance liver lesions in mice with Budd-Chiari syndrome.
J Hepatol
; 68(5): 1086-1087, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360553
15.
Thrombospondin-1 is not the major activator of TGF-ß1 in thrombopoietin-induced myelofibrosis.
Blood
; 117(1): 246-9, 2011 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-20944070
16.
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
Leukemia
; 37(6): 1287-1297, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37100881
17.
Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation.
Blood
; 116(25): 5670-8, 2010 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20829371
18.
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
Blood
; 116(5): 783-7, 2010 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20472827
19.
Lessons from mouse models of MPN.
Int Rev Cell Mol Biol
; 366: 125-185, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35153003
20.
In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target.
Blood Cancer Discov
; 3(4): 285-297, 2022 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35290450